Omalizumab serum levels predict treatment outcomes in patients with chronic spontaneous urticaria: A three‐month prospective study

Ghazanfar, Misbah Noshela; Bartko, Ewa A.; Arildsen, Nicolai Skovbjerg; Poulsen, Lars K.; Jensen, Bettina M.; Enevold, Christian; Holm, Jesper Grønlund; Woetmann, Anders; Ødum, Niels; Thomsen, Simon Francis

doi:10.1111/cea.14121

Cited by 3 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other markers that may predict response to omalizumab include trough concentrations of serum omalizumab [ 105 ], expression of FcεRI [ 100 ] (especially on basophils [ 106 ]), eosinopenia [ 107 ], antinuclear antibodies [ 108 ], basophil CD203c activity [ 109 ], previous immunosuppressant treatment, D-dimer, and IL-31 [ 100 , 101 ]. In a retrospective study of patients with CSU from a single center, a good response to omalizumab was associated with patients who were atopic (high eosinophils, basophils, and IgE) and a poor response was associated with comorbid psychiatric disease and thyroid antibodies [ 110 ].…”

Section: Omalizumabmentioning

confidence: 99%

Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status

Casale,

Gimenez-Arnau,

Bernstein

et al. 2023

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Chronic spontaneous urticaria (CSU) is a debilitating inflammatory disorder of the skin, characterized by a fluctuating natural history, a complex mechanism of action, and a significant burden on patients, including effect on quality of life, development of psychosocial disorders, and a range of comorbidities. Recent international guidelines recommend a therapeutic approach of first-line treatment with second generation H1-antihistamines and second-line treatment with the biologic omalizumab. Here, the salient aspects of CSU and current status of data for omalizumab for patients with CSU are reviewed, with a focus on mechanism of action, efficacy and real-world effectiveness (including patient outcomes, response, relapse, and remission), and safety (including consideration of the risk of anaphylaxis). The review also considers recent data on COVID-19, CSU, and omalizumab and presents our perspective on future needs. Overall, the data suggest that omalizumab is an effective and well-tolerated treatment for patients with CSU that provides benefits for a wide range of patients.

show abstract

Section: Omalizumabmentioning

confidence: 99%

Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status

Casale,

Gimenez-Arnau,

Bernstein

et al. 2023

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

Omalizumab serum levels predict treatment outcomes in patients with chronic spontaneous urticaria: A three‐month prospective study

Ghazanfar

Bartko

Arildsen

et al. 2022

Clin Experimental Allergy

Self Cite

View full text Add to dashboard Cite

Therapies for Chronic Spontaneous Urticaria: Present and Future Developments

Asero,

Calzari,

Vaienti

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Chronic spontaneous urticaria (CSU) is a complex dermatological condition characterized by recurrent wheals and/or angioedema lasting for more than six weeks, significantly impairing patients’ quality of life. According to European guidelines, the first step in treatment involves second-generation H1-antihistamines (sgAHs), which block peripheral H1 receptors to alleviate symptoms. In cases with inadequate responses, the dose of antihistamines can be increased by up to fourfold. If symptoms persist despite this adjustment, the next step involves the use of omalizumab, a monoclonal anti-IgE antibody, which has shown efficacy in the majority of cases. However, a subset of patients remains refractory, necessitating alternative treatments such as immunosuppressive agents like cyclosporine or azathioprine. To address these unmet needs, several new therapeutic targets are being explored. Among them, significant attention is being given to drugs that block Bruton’s tyrosine kinase (BTK), such as remibrutinib, which reduces mast cell activation. Therapies like dupilumab, which target the interleukin-4 (IL-4) and IL-13 pathways, are also under investigation. Additionally, molecules targeting the Mas-related G protein-coupled receptor X2 (MRGPRX2), and those inhibiting the tyrosine kinase receptor Kit, such as barzolvolimab, show promise in clinical studies. These emerging treatments offer new options for patients with difficult-to-treat CSU and have the potential to modify the natural course of the disease by targeting key immune pathways, helping to achieve longer-term remission. Further research is essential to better elucidate the pathophysiology of CSU and optimize treatment protocols to achieve long-term benefits in managing this condition. Altogether, the future of CSU treatments that target pathogenetic mechanisms seems promising.

show abstract

Omalizumab serum levels predict treatment outcomes in patients with chronic spontaneous urticaria: A three‐month prospective study

Cited by 3 publications

References 10 publications

Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status

Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status

Omalizumab serum levels predict treatment outcomes in patients with chronic spontaneous urticaria: A three‐month prospective study

Therapies for Chronic Spontaneous Urticaria: Present and Future Developments

Contact Info

Product

Resources

About